Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : US46116X1019
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 29.4 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.11 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 31.23 | |||||
Beneish M-Score | 220.95 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 147 | |||||
3-Year EBITDA Growth Rate | 20.3 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 26.5 | |||||
3-Year Book Growth Rate | -9.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 291.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 41 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.81 | |||||
9-Day RSI | 52.46 | |||||
14-Day RSI | 53.35 | |||||
6-1 Month Momentum % | 40.43 | |||||
12-1 Month Momentum % | 11.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.41 | |||||
Quick Ratio | 5.31 | |||||
Cash Ratio | 4.03 | |||||
Days Inventory | 321.87 | |||||
Days Sales Outstanding | 74.14 | |||||
Days Payable | 105.21 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.2 | |||||
Shareholder Yield % | 0.09 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 92.7 | |||||
Operating Margin % | -34.49 | |||||
Net Margin % | -30.22 | |||||
FCF Margin % | -26.87 | |||||
ROE % | -22.65 | |||||
ROA % | -19.2 | |||||
ROIC % | -122.51 | |||||
ROC (Joel Greenblatt) % | -161.6 | |||||
ROCE % | -25.26 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 15.24 | |||||
PB Ratio | 11.75 | |||||
Price-to-Tangible-Book | 11.75 | |||||
EV-to-EBIT | -44.84 | |||||
EV-to-Forward-EBIT | -69.36 | |||||
EV-to-EBITDA | -44.99 | |||||
EV-to-Forward-EBITDA | -77.01 | |||||
EV-to-Revenue | 15.46 | |||||
EV-to-Forward-Revenue | 10.83 | |||||
EV-to-FCF | -57.55 | |||||
Price-to-Net-Current-Asset-Value | 13.09 | |||||
Price-to-Net-Cash | 19.23 | |||||
Earnings Yield (Greenblatt) % | -2.23 | |||||
FCF Yield % | -1.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITCI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 462.175 | ||
EPS (TTM) ($) | -1.46 | ||
Beta | 0.88 | ||
Volatility % | 36.81 | ||
14-Day RSI | 53.35 | ||
14-Day ATR ($) | 3.504735 | ||
20-Day SMA ($) | 70.201 | ||
12-1 Month Momentum % | 11.81 | ||
52-Week Range ($) | 45.5 - 84.89 | ||
Shares Outstanding (Mil) | 104.33 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Intra-Cellular Therapies Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(ITCI)'s stock price today?
When is next earnings date of Intra-Cellular Therapies Inc(ITCI)?
Does Intra-Cellular Therapies Inc(ITCI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |